What about confidence intervals? A word of caution when interpreting PTA simulations

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2502-2508

  Colin, Pieter ^a,b   Eleveld, Douglas J ^b   Jonckheere, Stijn ^c   Van Bocxlaer, Jan ^a   De Waele, Jan ^d   Vermeulen, An ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Clinical Microbiology OLV Aalst   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CONFIDENCE INTERVAL; HUMAN; PHARMACOKINETICS; STATISTICAL MODEL;

CONFIDENCE INTERVALS; HUMANS; MODELS, STATISTICAL; PHARMACOKINETICS;

EID: 85021431706     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw150     Document Type: Article

References (26)

1. Labreche MJ, Graber CJ, Nguyen HM. Recent updates on the role of pharmacokinetics-pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice. Clin Infect Dis 2015; 61: 1446-52.
2. Cojutti P, Maximova N, Pea F. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients. Antimicrob Agents Chemother 2015; 59: 5535-41.
3. Jaruratanasirikul S, Thengyai S, Wongpoowarak W et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother 2015; 59: 2995-3001.
4. Matsuo Y, Ishibashi T, Shimamura K et al. Prediction of pharmacokinetics and pharmacodynamics of doripenem in pediatric patients. J Pharm Sci 2015; 104: 3194-8.
5. Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 2015; 35: 127-39.
6. Mei Q, Ye Y, Zhu YL et al. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2015; 45: 652-6.
7. Bonate PL, Strougo A, Desai A et al. Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective. AAPS J 2012; 14: 749-58.
8. Dykstra K, Mehrotra N, Tornoe CWet al. Reporting guidelines for population pharmacokinetic analyses. J Clin Pharmacol 2015; 55: 875-87.
9. Wade JR, Edholm M, Salmonson T. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J 2005; 7: 45.
10. Efron B. The bootstrap and Markov-chain Monte Carlo. J Biopharm Stat 2011; 21: 1052-62.
11. Funatogawa T, Funatogawa I, Yafune A. Profile likelihood-based confidence intervals using Monte Carlo integration for population pharmacokinetic parameters. J Biopharm Stat 2006; 16: 193-205.
12. Nielsen E. FL, Karlsson M. Target attainment analysis to evaluate dosing regimens of an oral b-lactam antibiotic. In: Abstracts of Population Approach Group Europe, Venice, 2012. Abstract 2490. www.pagemeeting. org/?abstract=2490.
13. Savic RM, Ruslami R, Hibma JE et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the antituberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther 2015; 98: 622-9.
14. Canton R, Canut A, Morosini MI et al. Breakpoints for carbapenemaseproducing Enterobacteriaceae: is the problem solved? Enferm Infecc Microbiol Clin 2014; 32 Suppl 4: 33-40.
15. Canut A, Isla A, Rodriguez-Gascon A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 2015; 45: 399-405.
16. Carlier M, Roberts JA, Stove V et al. A simulation study reveals lack of pharmacokinetic/pharmacodynamic target attainment in de-escalated antibiotic therapy in critically ill patients. Antimicrob Agents Chemother 2015; 59: 4689-94.
17. Chung EK, CheathamSC, Fleming MR et al. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol 2015; 55: 899-908.
18. Jaruratanasirikul S, WongpoowarakW, Jullangkoon M et al. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia. J Pharmacol Sci 2015; 127: 164-9.
19. Udy AA, Lipman J, Jarrett P et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015; 19: 28.
20. Wicha SG, Haak T, Zink K et al. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. J Clin Pharmacol 2015; 55: 639-46.
21. Wu XJ, Zhang J, Guo BN et al. Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers. Antimicrob Agents Chemother 2015; 59: 1446-54.
22. Xiao AJ, Miller BW, Huntington JA et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016; 56: 56-66.
23. Yokoyama Y, Matsumoto K, Ikawa K et al. Population pharmacokineticpharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections. J Infect Chemother 2015; 21: 284-9.
24. Foracchia M, Hooker A, Vicini P et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74: 29-46.
25. Bazzoli C, Retout S, Mentre F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 2010; 98: 55-65.
26. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.